# The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS

> **NCT06176781** · PHASE3 · UNKNOWN · sponsor: **Simcere Pharmaceutical Co., Ltd** · enrollment: 880 (estimated)

## Conditions studied

- Subjects With Acute Ischemic Stroke

## Interventions

- **DRUG:** Edaravone Dexborneol Sequential Therapy
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06176781
- **Lead sponsor:** Simcere Pharmaceutical Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-28
- **Primary completion:** 2025-03-28
- **Final completion:** 2025-05-30
- **Target enrollment:** 880 (ESTIMATED)
- **Last updated:** 2023-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176781, "The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06176781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*